Literature DB >> 7014464

Protective immunity against murine candidiasis elicited by Candida albicans ribosomal fractions.

R Levy, E Segal, E Eylan.   

Abstract

Candida albicans ribosomes were prepared from mechanically disrupted cells through differential centrifugation and purification in a sucrose-ammonium sulfate solution. The ribosomes were analyzed chemically and physically and exhibited characteristics of eucaryotic ribosomes (78S). ICR female mice were immunized with two subcutaneous inoculations, 2 weeks apart, of 100 microgram of ribosomes (expressed as ribosomal protein). Immunized mice were challenged either intraperitoneally or intravenously with a lethal dose of live C. albicans cells. The 31-day survival rate of immunized mice challenged intraperitoneally was 64% (mean value) versus 27% in controls; in intravenously challenged mice the survival rate of the immunized animals was about 60%, with no survivors among the controls. In intravenously challenged mice, incomplete Freund adjuvant enhanced the protection elicited by the ribosomes. Protection by ribosomal immunization was obtained against challenge doses causing chronic and acute infection.

Entities:  

Mesh:

Year:  1981        PMID: 7014464      PMCID: PMC351400          DOI: 10.1128/iai.31.3.874-878.1981

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

Review 1.  Preparation of RNA and ribosomes from yeast.

Authors:  G M Rubin
Journal:  Methods Cell Biol       Date:  1975       Impact factor: 1.441

2.  UNIQUENESS OF BACTERIAL RIBOSOMES.

Authors:  M M TAYLOR; R STORCK
Journal:  Proc Natl Acad Sci U S A       Date:  1964-10       Impact factor: 11.205

3.  A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid.

Authors:  K BURTON
Journal:  Biochem J       Date:  1956-02       Impact factor: 3.857

4.  Immuno-stimulation by a ribosomal vaccine associated with a bacterial cell wall adjuvant in humans.

Authors:  F B Michel; L Dussourd D'Hinterland; J Bousquet; A M Pinel; G Normier
Journal:  Infect Immun       Date:  1978-06       Impact factor: 3.441

5.  Genetic relatedness of Candida albicans to asporogenous and ascosporogenous yeasts as reflected by nucleic acid homologies.

Authors:  E Segal; E Eylan
Journal:  Microbios       Date:  1974-01

6.  Differentiation of 23-S ribosomal RNA cistrons from 16-S ribosomal RNA cistrons in Escherichia coli by the sequence complementarity test.

Authors:  E Segal; M Osenholts; S A Yankofsky
Journal:  Biochim Biophys Acta       Date:  1973-04-21

7.  Pseudomonas ribosomal vaccines: preparation, properties, and immunogenicity.

Authors:  M M Lieberman
Journal:  Infect Immun       Date:  1978-07       Impact factor: 3.441

8.  Immunogenicity of ribosomal vaccines isolated from group A, type 14 Streptococcus pyogenes.

Authors:  W O Schalla; W Johnson
Journal:  Infect Immun       Date:  1975-06       Impact factor: 3.441

9.  Experimental murine candidiasis: pathological and immune responses to cutaneous inoculation with Candida albicans.

Authors:  D K Giger; J E Domer; J T McQuitty
Journal:  Infect Immun       Date:  1978-02       Impact factor: 3.441

10.  ACQUIRED IMMUNITY TO CANDIDIASIS IN MICE.

Authors:  H F HASENCLEVER; W O MITCHELL
Journal:  J Bacteriol       Date:  1963-09       Impact factor: 3.490

View more
  9 in total

1.  Influence of preformed antibody on the pathogenesis of experimental Candida albicans endocarditis.

Authors:  W M Scheld; R A Calderone; J P Brodeur; M A Sande
Journal:  Infect Immun       Date:  1983-06       Impact factor: 3.441

2.  Detection of antibodies against Candida albicans ribosomes by the enzyme linked immunosorbent assay.

Authors:  R Levy; E Segal; E Eylan
Journal:  Mycopathologia       Date:  1984-09-30       Impact factor: 2.574

3.  Protective ribosomal preparation from Shigella sonnei as a parenteral candidate vaccine.

Authors:  V I Levenson; T P Egorova; Z P Belkin; V G Fedosova; J L Subbotina; E Z Rukhadze; E K Dzhikidze; Z K Stassilevich
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

4.  Systemic candidiasis in mice immunized with Candida albicans ribosomes.

Authors:  R Levy; E Segal; L Barr-Nea
Journal:  Mycopathologia       Date:  1985-07       Impact factor: 2.574

5.  Cell-mediated immunity following experimental vaccinations with Candida albicans ribosomes.

Authors:  R Levy; E Segal; E Eylan; L Barr-Nea
Journal:  Mycopathologia       Date:  1983-11-25       Impact factor: 2.574

6.  Candida albicans-induced agglutinin and immunoglobulin E responses in mice.

Authors:  G E Winterrowd; J E Cutler
Journal:  Infect Immun       Date:  1983-07       Impact factor: 3.441

7.  Immune responses elicited by vaccinations with Candida albicans ribosomes in cyclophosphamide treated animals.

Authors:  E Segal; H Sandovsky-Losica; S Nussbaum
Journal:  Mycopathologia       Date:  1985-02       Impact factor: 2.574

Review 8.  Experimental in Vivo Models of Candidiasis.

Authors:  Esther Segal; Michael Frenkel
Journal:  J Fungi (Basel)       Date:  2018-02-06

Review 9.  Current trends to control fungal pathogens: exploiting our knowledge in the host-pathogen interaction.

Authors:  Laura C García-Carnero; Luis A Pérez-García; José A Martínez-Álvarez; Juana E Reyes-Martínez; Héctor M Mora-Montes
Journal:  Infect Drug Resist       Date:  2018-07-03       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.